MELANOMA: tratamiento de primera línea - page 9

CA209-067: Study Design

Presented By Jedd Wolchok at 2016 ASCO Annual Meeting

31’5% BRAF mutados

(1ª línea pura)

36’1% LDH elevada

23’6% PD-L1 positivo

FOLLOW UP 18 months

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1,2,3,4,5,6,7,8 10,11,12,13,14,15,16,17,18,19,...37